PMID- 20205489
OWN - NLM
STAT- MEDLINE
DCOM- 20100719
LR  - 20181113
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 70
IP  - 4
DP  - 2010 Mar 5
TI  - Tadalafil: in pulmonary arterial hypertension.
PG  - 479-88
LID - 10.2165/11204580-000000000-00000 [doi]
AB  - Tadalafil is a selective cyclic guanosine monophosphate-specific 
      phosphodiesterase type 5 inhibitor that is effective in improving exercise 
      ability, the time to clinical worsening and health-related quality of life 
      (HR-QOL) scores in patients with pulmonary arterial hypertension (PAH). In a 
      large, 16-week, randomized, double-blind, placebo-controlled, multicentre, phase 
      III trial (PHIRST) in patients aged >or=14 years with PAH (WHO group I), 
      tadalafil 40 mg once daily (the recommended dosage) significantly increased the 
      mean placebo-corrected 6-minute walk distance (6MWD) by 33 m from baseline 
      (primary endpoint). In treatment-naive patients, tadalafil 40 mg once daily 
      significantly increased the mean placebo-corrected 6MWD by 44 m at week 16, 
      whereas in patients receiving bosentan 125 mg twice daily as background therapy 
      there was a mean change of 23 m, which was not significant. Both the time to the 
      first occurrence of clinical worsening and the incidence of clinical worsening 
      were significantly reduced in recipients of tadalafil 40 mg once daily compared 
      with recipients of placebo. Furthermore, at week 16, tadalafil improved most 
      HR-QOL outcomes from baseline to a significantly greater extent than placebo. 
      Preliminary data from an extension of the PHIRST trial suggest that the 
      improvements in 6MWD are maintained for up to 1 year in recipients of tadalafil 
      20 or 40 mg once daily. Treatment with tadalafil was generally well tolerated, 
      with adverse events that were transient in nature and of mild to moderate 
      intensity.
FAU - Croxtall, Jamie D
AU  - Croxtall JD
AD  - Adis, Auckland, New Zealand. demail@adis.co.nz
FAU - Lyseng-Williamson, Katherine A
AU  - Lyseng-Williamson KA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Carbolines)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 742SXX0ICT (Tadalafil)
SB  - IM
MH  - Carbolines/administration & dosage/adverse effects/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy
MH  - Phosphodiesterase Inhibitors/administration & dosage/adverse 
      effects/pharmacology/therapeutic use
MH  - Tadalafil
RF  - 31
EDAT- 2010/03/09 06:00
MHDA- 2010/07/20 06:00
CRDT- 2010/03/09 06:00
PHST- 2010/03/09 06:00 [entrez]
PHST- 2010/03/09 06:00 [pubmed]
PHST- 2010/07/20 06:00 [medline]
AID - 8 [pii]
AID - 10.2165/11204580-000000000-00000 [doi]
PST - ppublish
SO  - Drugs. 2010 Mar 5;70(4):479-88. doi: 10.2165/11204580-000000000-00000.